Expanded Access to Elezanumab

Study Identifier
C20-203
CT.gov Identifier
NCT04278235
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Study Details

Medical Condition
  • Neuroscience - Other
    • Study Drug
  • Elezanumab
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    Exclusion Criteria: * There are other suitable treatment options. * The participant qualifies for ongoing clinical trials.

    Protocol Summary

    This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Elezanumab prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

    Study Locations

    No locations found.